Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Will AbbVie And These Two Other Drug Stocks Reinvigorate — Or Incinerate?

A bullish first-quarter report could reinvigorate AbbVie stock, an analyst said Thursday after a C-suite setback this week.

Investors Business Daily

Executives Sell Over $44M Of 4 Stocks

Although gold futures traded slightly lower on Friday, there were a few notable insider trades.

Benzinga

Will New Buys By The Best Mutual Funds Prop Up These Big-Name, But Pressured Stocks?

Making the latest list of new buys by the best mutual funds, Apple and GOOGL face headwinds, while Vertex and Lilly weather the storm.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Top S&P 500 Stock Market Gainers Today; Eli Lilly Leads Winners As Casinos Are Bad Bet

Eli Lilly rallied to a new high and was Wednesday's top S&P 500 performer. Norwegian Cruise Line led the big-cap losers.

Investors Business Daily

Eli Lilly Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 37 strange trades.

Benzinga

Where Eli Lilly Stands With Analysts

Over the past 3 months, 5 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

US pulls GSK's COVID drug as omicron sibling dominates cases

U.S. regulators say GlaxoSmithKline’s COVID-19 antibody drug should no longer be used because it is likely ineffective against the latest version of the virus that accounts for most cases

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Alphabet And 2 Other Stocks Insiders Are Selling

Although the Nasdaq Composite dropped around 2% on Tuesday, there were a few notable insider trades.

Benzinga

Peering Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 22.39% since its last report. The company recently reported that it has 6.50 million shares sold short, which is 0.82% of all regular shares that are available for trading.

Benzinga

Exxon Mobil, Google Lead Five Stocks Near Buy Points For Resilient Portfolio

Exxon Mobil and Google are among five stocks near buy points. A diverse portfolio can be more resilient amid market shifts.

Investors Business Daily

If You Invested $100 In Eli Lilly 10 Years Ago, Here's How Much You Would Have Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.2% on an annualized basis producing an average annual return of 21.76%. Currently, Eli Lilly has a market capitalization of $274.87 billion.

Benzinga

As Eli Lilly Holds Above Breakout Level, Here Are Two Option Trade Ideas

The stock is trading above its 50-day and 200-day moving averages and those moving averages are sloping upward.

Investors Business Daily

How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag

The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.

Investors Business Daily

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Financial Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Looking Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 13.56% since its last report. The company recently reported that it has 5.36 million shares sold short, which is 0.67% of all regular shares that are available for trading.

Benzinga

Check Out What Whales Are Doing With LLY

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease

Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).

Investors Business Daily

Top Funds Pump Money Into Eli Lilly As It Nears Breakout With Rising Relative Strength

With Eli Lilly earning a spot on the list of new buys by top funds, LLY stock is setting up a new buy point as the market correction continues.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

These Four Exceptions Prove You Can Still Make Money In Medical Stocks

Bristol Myers, Eli Lilly and two others prove you can still make money investing in medical stocks — if you know where to look.

Benzinga

Here's How Much $100 Invested In Eli Lilly 5 Years Ago Would Be Worth Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 13.68% on an annualized basis.

Investors Business Daily

Dow Jones Futures Fall After 'Ideal' Market Action; Inflation Report Due

Futures fall after Wednesday didn't trigger a market follow-through day. Crude oil prices are rising with a key inflation report due.

Benzinga

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

According to a British study, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients…

Benzinga

Eli Lilly And 3 Other Stocks Sold By Insiders

Although US crude oil futures traded higher this morning, there were a few notable insider trades.

Investors Business Daily

Eli Lilly Stock Shows Improved Relative Strength Performance With 84 RS Rating

A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance.

Benzinga

FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population

The FDA approved Eli Lilly And Co (NYSE:LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure…

1 … 28 29 30 31

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.